RenovoRx gets Nasdaq extension to Feb 19, 2024 for $2.5M equity compliance

RenovoRx, Inc.

Nasdaq granted extension to February 19, 2024 to meet $2.5M stockholders' equity requirement (Rule 5550(b)(2)).
Company must evidence full compliance by deadline; failure triggers delist determination.
Delist determination can be stayed by request for hearing before Nasdaq Hearings Panel.
No assurance of compliance; risk of delisting if not met.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.